Palatin Technologies, Inc. is a clinical-stage biopharmaceutical company focused on the development of peptide-based therapeutics that modulate G protein-coupled receptor (GPCR) activity. The company’s research centers on melanocortin receptors, which play critical roles in a range of physiological processes including sexual function, metabolic regulation, and inflammatory response. Palatin’s mission is to discover and advance novel peptide molecules into safe and effective medicines to address unmet medical needs.
Palatin’s product pipeline features several clinical and preclinical candidates targeting diverse indications. Its lead program, bremelanotide, is designed to treat female sexual dysregulation and has been licensed to an established specialty pharmaceutical partner for commercialization. Other pipeline assets include PL8177, a melanocortin-1 receptor agonist in development for inflammatory bowel disease and rheumatologic conditions, and PL9643, an investigational molecule targeting ocular surface disorders such as dry eye disease. The company leverages its proprietary peptide chemistry platform to engineer molecules with improved receptor selectivity, tissue targeting, and pharmacokinetic profiles.
Founded in 1983 and headquartered in Cranbury, New Jersey, Palatin operates with a lean, specialized team and collaborates with contract research organizations and academic institutions. Through strategic partnerships and licensing agreements, the company has extended its global reach, engaging regulatory and commercial expertise across North America, Europe, and select international markets. Palatin’s approach combines internal research capabilities with external collaborations to optimize resource allocation and accelerate development timelines.
Under the leadership of President and Chief Executive Officer Alan R. Walsh, Palatin Technologies is guided by a board of directors and management team with extensive experience in drug development, regulatory strategy, and commercial operations. The company remains committed to advancing its peptide therapeutics portfolio through rigorous clinical development, seeking to deliver new treatment options that can improve quality of life for patients worldwide.
AI Generated. May Contain Errors.
Free PTN Stock Alerts